// Biotech and Pharma Therapeutics
Multi-cancer blood tests aren’t ready for routine use, review says
September 23, 2025 / multi-cancer screening / blood-based cancer tests / cancer early detection / false positives cancer / MCD test accuracy
Multi-cancer blood tests show promise but lack sufficient evidence for routine screening use, with concerns about accuracy, false positives, and potential harm, according to a federal review published in Annals of Internal Medicine.
A Validated Regulatory Network for Th17 Cell Specification
September 23, 2025 / Th17 cell specification / flow cytometry error / transcription factors / IL-17A expression / data correction
A duplicated flow cytometry panel was identified in a 2012 Th17 cell specification study. The authors acknowledged the error, which they state does not affect the study’s conclusions, though original data to correct it remain missing.
Xeltis prepares for commercial launch after strong aXess trial results
September 24, 2025 / vascular access device / hemodialysis innovation / aXess trial results / end-stage renal disease / dialysis vascular conduit
Xeltis’ aXess vascular conduit showed superior patency, fewer interventions, and low infection rates in a successful EU phase 3 trial for dialysis patients, supporting its potential as a breakthrough in hemodialysis access. U.S. trials are underway.
Fiocruz links up with pharmas to produce medicine for SMA
September 24, 2025 / spinal muscular atrophy / nusinersen production Brazil / Fiocruz PDP partnership / SMA treatment access / biotech local manufacturing
Fiocruz, Hypera Pharma, and Aurisco have partnered to locally produce nusinersen for spinal muscular atrophy (SMA) in Brazil, aiming to improve access, reduce import reliance, and support national biotech capabilities under the Novo PAC Saúde initiative.
Acadia to scrap Prader-Willi drug after study setback
September 24, 2025 / Prader-Willi syndrome / ACP-101 trial failure / hyperphagia treatment / Acadia Pharmaceuticals pipeline / rare disease drug setback
Acadia is discontinuing development of ACP-101 for Prader-Willi syndrome after it failed to outperform placebo in a Phase 3 trial. Focus now shifts to other late-stage assets, including a potential treatment for Alzheimer’s disease psychosis.
// 4th Industrial Revolution
AI-guided platform improves design and efficiency of therapeutic nanoparticles
September 24, 2025 / AI drug delivery / nanoparticle formulation / leukemia treatment / therapeutic nanoparticles / TuNa-AI platform
Duke researchers developed TuNa-AI, an AI-guided platform that improves nanoparticle design for drug delivery, enhancing stability, safety, and efficacy—demonstrated with leukemia therapies. This approach could optimize treatment delivery for hard-to-encapsulate drugs across various diseases.
New app can help young adults with first-episode psychosis to better manage cannabis use
September 24, 2025 / psychosis and cannabis / harm reduction app / CHAMPS mobile tool / mental health innovation / youth cannabis management
Researchers in Canada developed CHAMPS, a mobile app to help young adults with first-episode psychosis manage cannabis use through harm reduction. Early results show promise in reducing cannabis-related issues while integrating seamlessly into clinical care.
The High Cost of Non-Adherence: AI-Powered Interventions Save Medicare $10M in Diabetes Care
September 24, 2025 / CGM adherence Medicare / AI in diabetes care / predictive analytics healthcare / chronic disease management / personalized patient engagement
AI-powered predictive interventions improved CGM adherence in Medicare diabetes patients, saving $10M by reducing complications and hospitalizations. Personalized outreach based on behavioral and clinical data highlights the value of proactive, tech-enabled chronic disease management.
The New Digital Frontier: How QHIN-Connected EHRs Level the Playing Field for Community Hospitals
September 24, 2025 / healthcare collaboration / AI automation / clinical communication tools / virtual healthcare support / real-time translation
QHIN-connected EHRs empower community hospitals to exchange patient data nationally, improve documentation, boost revenue integrity, and maintain independence. This TEFCA-driven interoperability enhances care coordination and financial performance without requiring consolidation into larger health systems.
Wearable device uses AI and bioelectronics to personalize wound therapy
September 23, 2025 / AI wound healing / personalized wound therapy / wearable bioelectronics / chronic wound treatment / a-Heal device
UC Santa Cruz engineers developed “a-Heal,” a wearable device using AI, imaging, and bioelectronics to personalize wound treatment. It accelerates healing by adapting therapy in real time, showing 25% faster recovery in preclinical models.
// Business & Markets
Healthcare’s Security Awakening Testing Patience of Medical Device Buyers
September 24, 2025 / medical device cybersecurity / FDA device warning / secure-by-design healthcare / hospital cyberattacks / healthcare technology procurement
Healthcare providers are prioritizing cybersecurity in medical device procurement, with many rejecting vendors lacking secure-by-design features. Following regulatory warnings and costly breaches, buyers now demand robust protections, transparency, and are willing to pay more for secure, patient-safe technologies.
Texas next in Lilly’s US manufacturing drive
September 24, 2025 / Eli Lilly expansion / API manufacturing Texas / orforglipron production / small molecule therapies / Houston pharmaceutical facility
Eli Lilly plans a $6.5B API manufacturing facility in Houston to support production of small molecule therapies, including orforglipron, across cardiometabolic, oncology, immunology, and neuroscience pipelines. The site aims to be operational within five years.
Sanofi Ventures banks $625M to back young biotechs, digital health startups
Sanofi Ventures has added $625M to support early- to late-stage biotechs and digital health startups, targeting areas like immunology, neurology, and rare diseases. The fund aims to drive innovation and strategic partnerships amid tighter biotech funding.
New $10 million initiative aims to tailor diets for Canadians living with IBD
September 23, 2025 / IBD personalized nutrition / gut microbiome AI / Crohn’s diet research / ulcerative colitis management / RapidAIM dietary tool
A $10M initiative led by uOttawa will develop an AI-driven tool to personalize dietary strategies for IBD patients by analyzing individual gut microbiome responses to carbohydrates, aiming to improve disease management and quality of life.
Capital Rx Rebrands as Judi Health After Securing $400M Investment
September 23, 2025 / Judi Health rebrand / pharmacy benefit manager / healthcare platform investment / PBM innovation 2025 / digital health navigation
Capital Rx has rebranded as Judi Health after securing $400M in funding to expand beyond pharmacy benefits. The company will enhance its Enterprise Health Platform, integrating PBM services with medical, vision, dental, and care navigation support.
// Legal & Regulatory
UniQure to seek approval of Huntington’s gene therapy after trial win
September 24, 2025 / Huntington’s gene therapy / AMT-130 clinical trial / UniQure FDA approval / neurodegenerative disease treatment / gene therapy breakthrough
UniQure will seek FDA approval in 2026 for its gene therapy AMT-130 after Phase 2 data showed a 75% reduction in Huntington’s disease progression over three years, marking a potential breakthrough for this fatal neurodegenerative disorder.
Biogen plots resubmission after FDA turns down high-dose Spinraza in SMA, requests more production info
September 24, 2025 / Spinraza high dose / SMA treatment FDA / Biogen CRL response / nusinersen Devote trial / SMA manufacturing delay
The FDA issued a CRL to Biogen for high-dose Spinraza in SMA, citing manufacturing documentation—not clinical data—as the issue. Biogen plans a prompt resubmission, backed by strong efficacy results from its Devote trial in infantile-onset SMA.
Biogen gets CRL for high dose nusinersen
September 24, 2025 / high dose nusinersen / SMA treatment update / Biogen FDA response / CMC regulatory requirements / Spinraza sNDA resubmission
The FDA issued a CRL for Biogen’s high-dose nusinersen sNDA for SMA, citing technical updates needed in the CMC section. No clinical data issues were identified, and Biogen plans a prompt resubmission.
Glooko Acquires Monarch Medical to Unify Diabetes Management
September 23, 2025 / Glooko diabetes platform / inpatient glycemic control / EndoTool insulin dosing / digital health acquisition / remote diabetes management
Glooko has acquired Monarch Medical Technologies to integrate inpatient and outpatient diabetes management. By adding EndoTool’s precision insulin dosing platform, Glooko aims to enhance glycemic control, reduce readmissions, and support continuity of care across clinical settings.
Biotech Rival Files Antitrust and Patent-Infringement Claims Against Illumina
September 23, 2025 / Illumina lawsuit 2025 / DNA sequencing monopoly / biotech patent infringement / antitrust life sciences / genomic technology litigation
A biotech company has filed antitrust and patent infringement lawsuits against Illumina, alleging it holds an unlawful monopoly over the global next-generation DNA sequencing market, potentially impacting competition and innovation in genomic technologies.
// Research & Development
Tylenol in pregnancy linked to higher autism risk, Harvard scientists report
September 24, 2025 / acetaminophen pregnancy risk / autism ADHD link / Tylenol prenatal exposure / neurodevelopmental disorders study / Harvard acetaminophen research
A Harvard-led review of 46 studies suggests prolonged acetaminophen use during pregnancy may be linked to increased risk of autism and ADHD in children. Experts recommend cautious, short-term use under medical supervision while further research continues.
Driving Success in Active-Controlled Clinical Trials with Real-World Data
September 24, 2025 / real-world data integration / active-controlled trials / comparator drug safety / clinical trial design / regulatory decision support
Real-world data (RWD) enhances active-controlled clinical trials by addressing safety and efficacy gaps in comparator drugs, especially older therapies lacking diverse or long-term data. Integrating RWD ensures more accurate, equitable, and regulatory-aligned treatment evaluations.
Harmony’s pivotal Fragile X trial flops as high placebo response creates discord
September 24, 2025 / Fragile X clinical trial / ZYN002 trial failure / Harmony Biosciences setback / cannabidiol neurodevelopmental treatment / placebo effect in trials
Harmony Biosciences’ Phase 3 trial of ZYN002 for Fragile X syndrome failed to meet its primary endpoint, likely due to high placebo response. The setback casts doubt on the program’s future and diminishes the value of its Zynerba acquisition.
BMS Phase III success with iberdomide
September 24, 2025 / iberdomide Phase III / multiple myeloma treatment / MRD negativity improvement / BMS clinical trial / CELMoD combination therapy
Bristol Myers Squibb’s Phase III EXCALIBER-RRMM trial showed iberdomide significantly improved MRD negativity in relapsed/refractory multiple myeloma patients. The study continues to evaluate progression-free survival and overall survival. Safety remains consistent with prior data.
North Star shows promise in phase 2 thyroid trial
September 24, 2025 / desiccated thyroid extract / North Star hypothyroidism / DTE Phase 2 trial / levothyroxine conversion study / Acella Neuvosyn FDA
Acella and Neuvosyn’s Phase 2 trial of North Star, a desiccated thyroid extract (DTE), met its primary endpoint in defining levothyroxine conversion and showed a favorable safety profile, advancing efforts toward FDA approval for hypothyroidism treatment.
// Politics
Disparity in vaccine access between states roils patients, providers
September 23, 2025 / pediatric COVID vaccine / vaccine access disparity / state health policy / public health fragmentation / provider vaccine challenges
COVID-19 vaccine access for children has become fragmented across U.S. states, driven by political decisions overriding medical guidance. This inconsistency is straining providers, confusing patients, and raising concerns about growing disparities in public health policy and disease prevention.
GlaxoSmithKline (GSK) Bets on Politics and U.S. Pipeline to Reclaim Pharma Prominence
September 24, 2025 / GSK Leucovorin revival / pharma political strategy / U.S. drug pipeline / GlaxoSmithKline comeback / oncology drug repositioning
GlaxoSmithKline is aiming to regain pharmaceutical prominence by leveraging U.S. political momentum to revive Leucovorin, a previously shelved therapy. The move highlights GSK’s strategic pivot toward its U.S. pipeline amid competition from Pfizer and Merck.
White House weighs creating ‘TrumpRx’ website where citizens can buy meds directly from pharma companies: report
September 23, 2025 / TrumpRx drug pricing / direct-to-consumer meds / White House pharma policy / U.S. medication access / federal health initiative
The Trump administration is considering launching “TrumpRx,” a federal website to connect Americans with pharmaceutical companies for direct, discounted medication purchases. The initiative aims to lower U.S. drug costs and pressure companies to expand direct-to-consumer options.
James Uthmeier says pharma company ordered to pay Florida $3M in HIV drug kickback lawsuit
September 24, 2025 / Gilead kickback lawsuit / HIV drug promotion / Medicaid fraud settlement / Florida healthcare enforcement / pharmaceutical legal accountability
Gilead Sciences will pay Florida $3 million to settle allegations of providing kickbacks to healthcare providers to promote HIV drugs, violating Medicaid rules. Similar cases in other states, including New York, have led to much larger settlements.
New Maine law to address ‘pharmacy deserts’
September 24, 2025 / pharmacy deserts Maine / rural prescription access / remote dispensing sites / telehealth pharmacy services / Maine pharmacy legislation
Maine’s new law targets rural “pharmacy deserts” by allowing remote dispensing sites with pharmacist supervision and telehealth counseling. The initiative aims to expand prescription access in underserved areas following widespread local pharmacy closures.